Key result
Morpholino-substituted anthracyclines increase activity against MDR tumors while Ring-B modifications show no benefit.
Population
Preclinical tumor models, including multidrug resistant (MDR) tumors
Comparison
Ring-B modified anthracyclines and… vs Parent anthracyclines (daunorubicin, doxorubicin)
Design
Review
Authors
Loading...
May support anthracycline redesign to limit cardiotoxicity; leaves open optimal modifications against multidrug-resistant tumors.
Activity on multidrug resistant tumors is driven by modifications in the sugar moiety rather than the aglycone ring-B of anthracyclines, though structural modifications remain important for reducing cardiotoxicity.
Suarato et al. (1999) conducted a review in Multidrug resistant (MDR) tumors. Ring-B modified anthracyclines was evaluated on Antitumor activity on multidrug resistant (MDR) tumors. Ring-B modifications of anthracyclines yielded promising pharmacological activity but did not modify activity on multidrug resistant tumors, whereas introducing a morpholino group increased activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: